Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Bayer, Onyx announce data from Nexavar Phase 3 trial on RAI-refractory differentiated thyroid cancer

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Sirtex unveils new website to learn more about SIR-Spheres microspheres

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Targeted therapy as common as chemotherapy at end of life

Targeted therapy as common as chemotherapy at end of life

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Tumour burden predicts prognosis in mRCC

Tumour burden predicts prognosis in mRCC

Scientists show how sorafenib can be dangerous to the heart

Scientists show how sorafenib can be dangerous to the heart

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Sorafenib does not improve overall survival among patients with NSCLC

Sorafenib does not improve overall survival among patients with NSCLC

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

AVEO submits tivozanib NDA with FDA for treatment of advanced renal cell carcinoma

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Important data from Pfizer’s lung cancer and RCC portfolios to be presented at ESMO Congress

Jennerex Phase 2 JX-594 clinical data for hepatocellular carcinoma presented at ILCA meeting

Jennerex Phase 2 JX-594 clinical data for hepatocellular carcinoma presented at ILCA meeting

Addition of sorafenib to chemotherapy does not prolong survival

Addition of sorafenib to chemotherapy does not prolong survival

Sorafenib could be effective against multiple myeloma

Sorafenib could be effective against multiple myeloma

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

EC grants marketing authorization for Pfizer’s INLYTA to treat renal cell carcinoma

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Bayer submits regorafenib NDA with FDA for treatment of metastatic and/or unresectable GIST

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Seattle Genetics commences everolimus-SGN-75 combination phase Ib clinical trial for advanced RCC

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

Jennerex initiates JX-594 Phase 2 trial in advanced hepatocellular carcinoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.